103 related articles for article (PubMed ID: 15195921)
1. Oligonucleotide, antibody and peptide therapeutics--from design to the clinic.
Goodchild J
Curr Opin Mol Ther; 2004 Apr; 6(2):119. PubMed ID: 15195921
[No Abstract] [Full Text] [Related]
2. Web alert. Oligonucleotide, antibody and peptide therapeutics.
Stephens AC
Curr Opin Mol Ther; 2003 Apr; 5(2):95-6. PubMed ID: 12772496
[No Abstract] [Full Text] [Related]
3. RNA-based therapeutics--from design to the clinic.
Iversen P
Curr Opin Mol Ther; 2009 Apr; 11(2):107. PubMed ID: 19330715
[No Abstract] [Full Text] [Related]
4. QC in antisense oligo synthesis.
Agris PF; Smith S; Fu C; Simkins SG
Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500
[No Abstract] [Full Text] [Related]
5. Oligonucleotides--from design to the clinic.
Bennett CF
Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
[No Abstract] [Full Text] [Related]
6. Peptide-oligonucleotide hybrids in antisense therapy.
Pierce TL; White AR; Tregear GW; Sexton PM
Mini Rev Med Chem; 2005 Jan; 5(1):41-55. PubMed ID: 15638791
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides in the design of new therapeutic strategies.
Piulats J; Tarrasón G
Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():31-2. PubMed ID: 9403853
[No Abstract] [Full Text] [Related]
8. Potent antibody therapeutics by design.
Carter PJ
Nat Rev Immunol; 2006 May; 6(5):343-57. PubMed ID: 16622479
[TBL] [Abstract][Full Text] [Related]
9. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.
Juliano RL
Ann N Y Acad Sci; 2006 Oct; 1082():18-26. PubMed ID: 17145920
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic peptides: technological advances driving peptides into development.
Sato AK; Viswanathan M; Kent RB; Wood CR
Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837
[TBL] [Abstract][Full Text] [Related]
11. EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industry.
Corey DR
IDrugs; 2006 Feb; 9(2):105-6. PubMed ID: 16523398
[No Abstract] [Full Text] [Related]
12. Adhesion molecule therapeutics in IBD.
Yacyshyn BR
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S279-80. PubMed ID: 18816743
[No Abstract] [Full Text] [Related]
13. Developing oligonucleotide therapeutics for human leukemia.
Gewirtz AM
Anticancer Drug Des; 1997 Jul; 12(5):341-58. PubMed ID: 9236851
[No Abstract] [Full Text] [Related]
14. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
Juliano RL
Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
[TBL] [Abstract][Full Text] [Related]
15. Sugar boost: when ribose modifications improve oligonucleotide performance.
Faria M; Ulrich H
Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
[TBL] [Abstract][Full Text] [Related]
16. An integrated science-based approach to drug development.
Parren PW; van de Winkel JG
Curr Opin Immunol; 2008 Aug; 20(4):426-30. PubMed ID: 18602995
[No Abstract] [Full Text] [Related]
17. Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.
Hermiston TW; Kirn DH
Mol Ther; 2005 Apr; 11(4):496-507. PubMed ID: 15771953
[TBL] [Abstract][Full Text] [Related]
18. Biotechnology and drug discovery--the future is here: a guide for the practicing urologist.
Avidor Y; Mabjeesh NJ; Pimenta I; Matzkin H
Urology; 2002 May; 59(5):643-51. PubMed ID: 11992833
[No Abstract] [Full Text] [Related]
19. Antisense technology: commercial implications.
Hawkins JW
Antisense Res Dev; 1991; 1(3):283-4. PubMed ID: 1821649
[No Abstract] [Full Text] [Related]
20. Antisense 98: work in progress.
Nat Biotechnol; 1998 Dec; 16(13):1319-21. PubMed ID: 9853610
[No Abstract] [Full Text] [Related]
[Next] [New Search]
